Moore David Scott
SEC Form 4 insider trading activity
Moore David Scott has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Jun 15, 2026.
On the most recent filing, Moore David Scott is listed as Director at Corvus Pharmaceuticals, Inc. Inside the rolling window, Moore David Scott reported 1 open-market purchase totaling $250K in CRVS and no open-market sales.
Companies traded
Other insiders at CRVS
Insider Buying
$250K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Moore David Scott made?
Moore David Scott has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Moore David Scott trade?
Moore David Scott has filed SEC Form 4 disclosures for 1 company, including CRVS.
When was Moore David Scott's most recent SEC Form 4 filing?
Moore David Scott's most recent SEC Form 4 filing on Tracefour is dated Jun 15, 2026.
What is Moore David Scott's total buy and sell value in the current window?
Inside the rolling retention window, Moore David Scott bought $250K and sold $0 based on SEC Form 4 filings.
What was Moore David Scott's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 21,700 CRVS shares on 2026-06-11, worth $250K, per SEC Form 4 filings.